Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($4.92), $1.84 better than the analyst estimate of ($6.76). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $34.09 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.